Combination of low-dose gemcitabine and recombinant quail vascular endothelial growth factor receptor-2 as a vaccine induces synergistic antitumor activities

Oncology

Volumn 69, Issue 1, 2005, Pages 81-87

  Hou, Jian Mei ^a   Liu, Ji Yan ^a,b   Yang, Li ^a   Zhao, Xia ^c   Tian, Ling ^a   Ding, Zhen Yu ^a   Wen, Yan Jun ^a   Niu, Ting ^a   Xiao, Fei ^a   Lou, Yan Yan ^a   Tan, Guang Hong ^a   Deng, Hong Xin ^a   Li, Jiong ^a   Yang, Jin Liang ^a   Mao, Yong Qiu ^a   Wei, Yu Quan ^a  

^a SICHUAN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^c SICHUAN UNIVERSITY   (China)

Author keywords

Gemcitabine; Tumor; Vaccine; Vascular endothelial growth factor

Indexed keywords

ANTINEOPLASTIC AGENT; GEMCITABINE; RECOMBINANT QUAIL VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 VACCINE; RECOMBINANT VACCINE; RECOMBINANT VASCULOTROPIN; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCING CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HISTOLOGY; IMMUNE RESPONSE; IMMUNOGLOBULIN DEPOSITION; LEWIS CARCINOMA; LIVER CELL CARCINOMA; MOUSE; NICK END LABELING; NONHUMAN; PANCREAS ISLET CELL TUMOR; PRIORITY JOURNAL; VACCINATION;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANCER VACCINES; CARCINOMA, LEWIS LUNG; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; FEMALE; IN SITU NICK-END LABELING; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; QUAIL; RANDOM ALLOCATION; VACCINES, SYNTHETIC; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 23944490634     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000087303     Document Type: Article

References (21)

1. Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82:4-6.
2. Watson SA, Morris TM, Robinson G, Crimmin MJ, Brown PD, Hardcastle JD: Inhibition of organ invasion by the matrix metalloproteinase inhibitor batimastat (BB-94) in two human colon carcinoma metastasis models. Cancer Res 1995;55:3629-3633.
3. Wei YQ, Huang MJ, Yang L, Zhao X, Tian L, Lu Y, Shu JM, Lu CJ, Niu T, Kang B, Mao YQ, Fen Liu, Wen YJ, Lei S, Luo F, Zhou LQ, Peng F, Jiang Y, Liu JY, Zhou H, Wang QR, He QM, Xiao F, Lou YY, Xie XJ, Li Q, Wu Y, Ding ZY, Hu B, Hu M, Zhang W: Immunogene therapy of tumors with vaccine based on Xenopus homologous vascular endothelial growth factor as a model antigen. Proc Natl Acad Sci USA 2001;98:11545-11550.
4. Gille H, Kowalski J, Li B, LeCouter J, Moffat B, Zioncheck TF, Pelletier N, Ferrara N: Analysis of biological effects and signaling properties of Flt-1(VEGFR-1) and KDR(VEGFR-2). J Biol Chem 2001;276:3222-3230.
5. Liu JY, Wei YQ, Yang L, Zhao X, Tian L, Hou JM, Niu T, Liu F, Jiang Y, Hu B, Wu Y, Su JM, Lou YY, He QM, Wen YJ, Yang JL, Kan B, Mao YQ, Luo F, Peng F: Immunotherapy of tumors with vaccine based on quail homologous vascular endothelial growth factor receptor-2. Blood 2003;102:1815-1823.
6. Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, Hofmann F, Mestan J, Mett H, O'Reilly T, Persohn E, Rösel J, Schnell C, Stover D, Theuer A, Towbin H, Wenger F, Woods-Cook K, Menrad A, Siemeister G, Schirner M, Thierauch KH, Schneider MR, Drevs J, Martiny-Baron G, Totzke F, Marmé D: PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor induced responses and tumor growth after oral administration. Cancer Res 2000;60:2178-2189.
7. Xiao F, Wei YQ, Yang L, Zhao X, Tian L, Ding ZY, Yuan SL, Lou Y, Liu F, Wen YJ, Li J, Deng HX, Kang B, Mao YQ, Lei S, He QM, Su JM, Lu Y, Niu T, Hou JM, Huang MJ: A gene therapy for cancer based on the angiogenesis inhibitor, vasostatin. Gene Ther 2002;9:1207-1213.
8. Prewett M, Huber J, Li YW, Santiago A, O'Connor W, King K, Overholser J, Hooper A, Pytowski B, Witte L, Bohlen P, Hicklin DJ: Antivascular endothelial growth factor receptor (Fetal Liver Kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 1999;59:5209-5218.
9. Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D, Yancopoulos GD, Wiegand SJ: Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999;284:1994-1998.
10. Kerbel RS: Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistence to anti-cancer therapeutic agents. Bioessays 1991;13:31-36.
11. Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, Bohlen P, Kerbel RS: Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000;105:15-24.
12. Borgstrom P, Gold DP, Hillan KJ, Ferrara N: Importance of VEGF for breast cancer angiogenesis in vivo: Implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin. Anticancer Res 1999;19:4203-4214.
13. Sweeney CJ, Miller KD, Sissons SE, Nozaki S, Heilman DK, Shen JZ, Sledge GW Jr: The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res 2001;61:3369-3372.
14. Jung CP, Motwani, MV, Schwartz GK: Flavopiridol increases sensitization to gemcitabine in human gastrointestinal cancer cell lines and correlates with down-regulation of ribonucleotide reductase M2 subunit. Clin Cancer Res 2001;7:2527-2536.
15. Hertel LW, Boder GB, Kroin JS, Rinzel SM, Poore GA, Todd GC, Grindey GB: Evaluation of the antitumor activity of gemcitabine (2-2-difluoro-2- deoxycytidine). Cancer Res 1990;50:4417-4422.
16. Czerkinsky CC, Nilsson LA, Nygren H, Ouchterlony O, Tarkowski A: A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells. J Immunol Methods 1983;65:109-121.
17. Wei YQ, Wang QR, Zhao X, Yang L, Tian L, Lu Y, Kang B, Lu CJ, Huang MJ, Lou YY, Xiao F, He QM, Shu JM, Xie XJ, Mao YQ, Lei S, Luo F, Zhou LQ, Liu CE, Zhou H, Jiang Y, Peng F, Yuan LP, Li Q, Wu Y, Liu JY: Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine. Nat Med 2000;6:1160-1166.
18. Dings RPM, Yokoyama Y, Ramakrishnan S, Griffioen AW, Mayo KH: The designed angiostatic peptide anginex synergistically improves chemotherapy and anti-angiogenesis therapy with angiostatin. Cancer Res 2003;63:382-385.
19. Kerbel RS: Tumor angiogenesis: Past, present and the near future. Carcinogenesis 2000;21:505-515.
20. Huang P, Plunkett W: Induction of apoptosis by gemcitabine. Semin Oncol 1995;22:19-25.
21. Keyes K, Cox K, Treadway P, Mann L, Shih C, Faul MM, Teicher BA: An in vitro tumor model: Analysis of angiogenic factor expression after chemotherapy. Cancer Res 2002;62:5597-5602.